Comparing drug-eluting stents and drug-coated balloons for coronary artery disease treatment
Official title: Intracoronary Stenting and Restenosis - Randomized Trial of Drug-eluting Stent Implantation or Drug-coated Balloon Angioplasty According to Neointima Morphology in Drug-eluting Stent Restenosis 5
Run by Deutsches Herzzentrum Muenchen · NCT05544864 · Data updated 2026-11-12
This study is testing whether drug-eluting stents or drug-coated balloons work better for patients with coronary artery disease who have had a previous stent and are experiencing symptoms again.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 376 (estimated) |
| Sponsor | Deutsches Herzzentrum Muenchen Academic / other |
| Locations | 5 sites (Frankfurt am Main, Hesse and 4 other locations) |
| Status | Recruiting |
| Started | September 28, 2022 |
| Main results expected | September 2026 |
| Study ends | September 2026 |
| Registry record updated | January 6, 2025 |
| Trial ID | NCT05544864 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults over 18 with ischemic symptoms and at least 50% restenosis after prior drug-eluting stent placement.
✕Probably not a fit
Patients with acute myocardial infarction, severe renal insufficiency, or those requiring additional coronary interventions within 30 days may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study investigates the effectiveness of drug-eluting stents versus drug-coated balloons in patients experiencing restenosis after previous stent implantation. It focuses on the interaction between the morphology of neointima, as assessed by optical coherence tomography (OCT), and the type of intervention used. Patients with significant restenosis and ischemic symptoms will be randomized to receive either treatment, with the aim of determining which approach yields better outcomes based on neointima characteristics.
Why it matters
Potential benefit: If successful, this study could lead to more personalized and effective treatment options for patients with coronary artery disease and stent restenosis.
How similar studies have gone: Previous studies have shown varying success with drug-eluting stents and drug-coated balloons, but this specific approach based on neointima morphology is novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients with ischemic symptoms and/or evidence of myocardial ischemia 2. Presence of ≥ 50% restenosis after prior implantation of drug-eluting stents in native coronary vessels. 3. Availability of an OCT-pullback of the target lesion 4. Written informed consent by the patient for participation in the study. 5. Age ≥ 18 years Exclusion Criteria: 1. Cardiogenic shock 2. Acute ST-elevation myocardial infarction within 48 hours from symptom onset. 3. Target lesion located in left main trunk or bypass graft. 4. Additional coronary intervention planned within 30 days of the procedure. 5. Non-successful treatment of other lesion(s) during the same procedure 6. Severe renal insufficiency (glomerular filtration rate ≤ 30 ml/min) 7. Contraindications to any components of the investigational devices or dual antiplatelet therapy 8. Pregnancy (present, suspected or planned) or positive pregnancy test. 9. Previous enrollment in this trial or participation in any other study at the time of enrollment. 10. Malignancies or other comorbid conditions with life expectancy less than 12 months or that may result in protocol non-compliance. 11. Patient's inability to fully comply with the study protocol
Where it's running
-
Universitätsklinikum Frankfurt
Frankfurt am Main, Hesse, Germany Recruiting -
Elisabeth-Krankenhaus Essen GmbH
Essen, Germany Recruiting -
Universitätsklinikum Hamburg-Eppendorf
Hamburg, Germany Recruiting -
Deutsches Herzzentrum München
Munich, Germany Recruiting -
Hospital Universitario de La Princesa Madrid
Madrid, Madrid, Spain Recruiting
Study contacts
- Study coordinator: Felix Voll, MD
- Email: voll@dhm.mhn.de
- Phone: +49 89 1218 2749
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
μFR-guided Drug-Coated Balloon Angioplasty vs Angiography-guided Angioplasty in Coronary Artery Disease
This trial tests whether using computational μFR guidance during drug-coated balloon angioplasty is better than standard angiography guidance for people with de novo coronary artery lesions.
-
Gastric Ultrasound Before CABG to See if Heart Function Changes Stomach Contents
This study checks whether people with weaker heart function before elective CABG have different stomach contents seen on ultrasound.
-
Can preoperative photon-counting CT help predict heart recovery after bypass surgery?
This observational study tests whether a preoperative photon-counting CT can help predict heart function 3 months after coronary bypass surgery in adults with coronary artery disease.
-
Real-World Drug-Coated Balloon Angioplasty in Coronary Artery Disease
This registry tests how drug-coated balloons perform in everyday clinical practice for adults with coronary artery disease undergoing PCI.
-
Predicting vasopressor needs after anesthesia in elective on-pump CABG using dynamic arterial elastance
This study tests whether EaDyn measured after induction can help predict which patients will need vasopressors during elective on-pump CABG.
-
Intraoperative Pulse Pressure Variation and Postoperative Lactate Clearance in CABG Patients
This study tests whether the amount a patient’s pulse pressure varies during surgery relates to how quickly lactate levels drop after CABG.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.